Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoCellular Therapeutics has announced that recently completed proof-of-principle studies demonstrate efficacy of its cancer stem cell vaccine technology in treating glioblastoma, a form of brain cancer, in preclinical animal models.
Subscribe to our email newsletter
The company is planning to submit an investigational new drug (IND) application to the FDA later 2008 to commence a Phase I clinical trial for its cancer stem cell vaccine product, ICT-111, to treat glioblastoma. The company’s cancer stem cell vaccine technology also could be applicable for multiple other cancers.
Manish Singh, president and CEO of IMUC, said: “We are excited about the data we have observed from the preclinical studies demonstrating a highly specific and potent immune response against cancer stem cells, as well as a survival advantage in the animals tested in preclinical studies.”